Health
FDA Approves Leucovorin for Rare Brain Condition Amid Autism Questions
Health Points
- Leucovorin is now the first FDA-approved treatment for cerebral folate deficiency.
- The drug is used to help address low brain vitamin B9 levels linked to this rare condition.
- Experts say more research is still needed before any broader use can be supported.
The FDA has officially approved leucovorin for treating cerebral folate deficiency in adults and children. This marks the first sanctioned treatment for a rare condition tied to low brain vitamin B9 levels.
Leucovorin has long been used as a chemotherapy rescue agent. In this setting, doctors hope it can help restore folate to healthy cells.
Experts say early intervention is important for managing seizures and developmental delays associated with the deficiency.
Although some officials have suggested broader possibilities, the agency has not approved leucovorin as an autism treatment. The Autism Science Foundation warns against false hope without stronger evidence.
Reliable data remain limited to small studies. Pediatricians are still waiting for larger trials to establish safety and efficacy for wider use.
“Today’s approval represents a significant milestone for patients living with cerebral folate transport deficiency due to the FOLR1 variant,” said FDA Commissioner Marty Makary, MD.
